Medicare Enrolled

Dr. James Lampasso, MD

Pulmonary Disease · Williamsville, NY
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
6460 MAIN ST, Williamsville, NY 14221
7166345100
In practice since 2005 (20 years)
NPI: 1902889090 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Lampasso from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lampasso? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Lampasso

Dr. James Lampasso is a pulmonary disease specialist in Williamsville, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lampasso performed 819 Medicare services across 553 unique beneficiaries.

Between the years covered by Open Payments, Dr. Lampasso received a total of $157,618 from 50 pharmaceutical and/or device companies across 1036 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Lampasso is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 47% volume in NY $157,618 industry payments

Medicare Practice Summary

Medicare Utilization ↗
819
Medicare services
Top 47% in NY for pulmonary disease
553
Unique beneficiaries
$77
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~41 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
311 $87 $145
Critical care, first 30-74 min
Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient.
133 $167 $689
Pulmonary gas exchange test
A test to examine how well the lungs exchange gases.
72 $40 $73
Lung volume test using gas dilution or washout
A test that measures the amount of air in your lungs by using a gas dilution or washout method.
70 $31 $59
Spirometry test before and after medication
A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication.
67 $27 $83
Inhaled albuterol and ipratropium bromide via DME
Administration of FDA-approved albuterol and ipratropium bromide medication through durable medical equipment.
66 $0 $5
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
32 $90 $259
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
31 $61 $105
Expiratory airflow and volume test
A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume.
21 $20 $50
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
16 $120 $235
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$157,618
Total received (2018-2024)
Avg $22,517/year across 7 years
Top 3% in NY for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
50
Companies
1,036
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$145,131 (92.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,488 (7.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$13,194
2023
$38,830
2022
$36,373
2021
$33,201
2020
$26,917
2019
$2,396
2018
$6,707

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$11,320
AstraZeneca Pharmaceuticals LP
$454
Mylan Specialty L.P.
$189
Merck Sharp & Dohme LLC
$166
Takeda Pharmaceuticals U.S.A., Inc.
$158
Boehringer Ingelheim Pharmaceuticals, Inc.
$152
Actelion Pharmaceuticals US, Inc.
$144
Regeneron Healthcare Solutions, Inc.
$120
Electromed, Inc.
$92
CSL Behring
$91
IDORSIA PHARMACEUTICALS US INC
$62
Grifols USA, LLC
$50
GENZYME CORPORATION
$49
Insmed, Inc.
$34
Amgen Inc.
$23
3B Medical, Inc.
$22
Pulmonx Corporation
$19
Bayer Healthcare Pharmaceuticals Inc.
$17
ABBVIE INC.
$16
Optinose US, Inc.
$15
Top 3 companies account for 90.7% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$141,234
AstraZeneca Pharmaceuticals LP
$6,086
Actelion Pharmaceuticals US, Inc.
$2,199
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,413
GENZYME CORPORATION
$730
Grifols USA, LLC
$713
Genentech USA, Inc.
$502
Bayer HealthCare Pharmaceuticals Inc.
$490
Mylan Specialty L.P.
$442
Regeneron Healthcare Solutions, Inc.
$416
Takeda Pharmaceuticals U.S.A., Inc.
$385
Electromed, Inc.
$297
Insmed, Inc.
$254
Gilead Sciences, Inc.
$203
Teva Pharmaceuticals USA, Inc.
$190
Merck Sharp & Dohme LLC
$183
Sunovion Pharmaceuticals Inc.
$174
Amgen Inc.
$144
CSL Behring
$111
Circassia Pharmaceuticals Inc
$109
Mallinckrodt Hospital Products Inc.
$104
Bayer Healthcare Pharmaceuticals Inc.
$87
Shire North American Group Inc
$85
Inogen, Inc.
$83
Philips Electronics North America Corporation
$77
IDORSIA PHARMACEUTICALS US INC
$62
Mallinckrodt Enterprises LLC
$60
Mallinckrodt LLC
$59
Jazz Pharmaceuticals Inc.
$57
ABBVIE INC.
$56
Baxter Healthcare
$55
Nabriva Therapeutics, plc
$50
Novartis Pharmaceuticals Corporation
$47
Allergan, Inc.
$45
Covis Pharma GmBH
$44
Axsome Therapeutics, Inc.
$44
Horizon Pharma plc
$39
United Therapeutics Corporation
$36
PFIZER INC.
$34
Allergan Inc.
$31
Optinose US, Inc.
$28
3B Medical, Inc.
$22
OptiNose US, Inc.
$19
Pulmonx Corporation
$19
JAZZ PHARMACEUTICALS INC.
$18
Eisai Inc.
$18
AbbVie Inc.
$18
Covis Pharma GmbH
$18
Paratek Pharmaceuticals, Inc.
$17
Janssen Pharmaceuticals, Inc
$11
Top 3 companies account for 94.9% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · AIRSUPRA · ALVESCO · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Adempas · AirDuo Digihaler · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CHARTIS CATHETER · Corlanor · DALVANCE · DUPIXENT · Dayvigo · Dymista · ELIQUIS · FARXIGA · FASENRA · GLASSIA · Hillrom - Life 2000 Ventilation System · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · InogenOne · Kcentra · LONHALA MAGNAIR · LUMIZYME · LUNA · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · PAXLOVID · Perforomist · ProAir Digihaler · Prolastin-C · Prolastin-C Liquid · QUVIVIQ · QVAR · RAYOS · Repatha · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Sivextro · Sunosi · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · UPTRAVI · UTIBRON · Utibron · WINREVAIR · Wellcentive Undiv · XOLAIR · Xenleta · Xhance · Xolair · Xyrem · YUPELRI · Yupelri · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for pulmonary disease in NY.

Looking for a pulmonary disease specialist in Williamsville?
Compare pulmonary diseases in the Williamsville area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary diseases within 10 mi
26
Per 100K population
2.7
County median income
$71,175
Nearest hospital
UPSTATE NEW YORK VA HEALTHCARE SYSTEM (WESTERN NY VA HEALTHCARE SYSTEM)
5.6 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Lampasso is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 3% of NY peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Lampasso experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Lampasso performed 311 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lampasso receive payments from pharmaceutical companies?
Yes. Dr. Lampasso received a total of $157,618 from 50 companies across 1,036 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lampasso's costs compare to other pulmonary diseases in Williamsville?
Dr. Lampasso's average Medicare payment per service is $77. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lampasso) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →